Literature DB >> 34702994

Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs.

Shaomin Hu1, Lindsay Alpert2, Justin M M Cates3, Raul S Gonzalez4.   

Abstract

Risk stratification of gastrointestinal stromal tumors (GISTs) is based on experience with tumors of the stomach, small bowel, and rectum, which are far more common than GISTs of other sites. In this study from 47 institutions, we analyzed GISTs of the esophagus (n = 102), colon (n = 136), and appendix (n = 27) for their size, mitotic rate, morphology, and outcome to determine which criteria predict their behavior. Esophageal GISTs were small (median: 2.5 cm) with spindle cell morphology and a low mitotic rate (mean: 3.6/5 mm2). Twelve (12%) tumors progressed, including 11 with a mitotic rate >5/5 mm2 and one large (6.8 cm) GIST with a mitotic rate of 2/5 mm2. Colonic GISTs were smaller (median: 1.4 cm) and presented with abdominal pain or bleeding in 29% of cases. Most (92%) were composed of spindle cells with a mean mitotic rate of 4.6/5 mm2. Sixteen (12%) tumors progressed: 14 had mitotic rates >5/5 mm2, and two were >5.0 cm with a mitotic rate <5/5 mm2. All but one appendiceal GIST measured <2.0 cm. These tumors were composed of spindle cells with low mitotic rates (<5/5 mm2), and none progressed. Our results suggest that progression risk among esophageal and colonic GISTs is associated with increased mitotic activity (>5/5 mm2) and size >5.0 cm. These findings support the use of size and mitotic rate for prognostication of GISTs in these locations, similar to tumors of the stomach, small bowel, and rectum.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Year:  2021        PMID: 34702994     DOI: 10.1038/s41379-021-00949-w

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

2.  Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome.

Authors:  Simon Lott; Michael Schmieder; Benjamin Mayer; Doris Henne-Bruns; Uwe Knippschild; Abbas Agaimy; Matthias Schwab; Klaus Kramer
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Prognostic factors affecting mortality in patients with esophageal GISTs.

Authors:  Dimitrios Schizas; George Bagias; Prodromos Kanavidis; Demetrios Moris; Eleftherios Spartalis; Christos Damaskos; Nikolaos Garmpis; Ioannis Karavokyros; Evangelos P Misiakos; Theodore Liakakos
Journal:  J BUON       Date:  2020 Jan-Feb       Impact factor: 2.533

Review 4.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.

Authors:  Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2010-05-05

5.  Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States.

Authors:  Nicolas Patel; Bikramjit Benipal
Journal:  Cureus       Date:  2019-02-22

6.  Colonic Gastrointestinal Stromal Tumor: A Population-Based Analysis of Incidence and Survival.

Authors:  Zhiqiang Liu; Yan Sun; Yongfeng Li; Jingyuan Zhao; Shihong Wu; Zibo Meng; Heshui Wu
Journal:  Gastroenterol Res Pract       Date:  2019-04-11       Impact factor: 2.260

  6 in total
  1 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.